Download - Biojax Blog 1

4/8/2015 TheBiojaxInvestingZone:March2015

http://webcache.googleusercontent.com/search?q=cache:gWB0KdfQPPMJ:biojaxusa.blogspot.com/2015_03_01_archive.html+&cd=1&hl=en&ct=clnk&gl=ch 1/5

ThisisGoogle'scacheofhttp://biojaxusa.blogspot.com/2015_03_01_archive.html.Itisasnapshotofthepageasitappearedon26Mar201502:47:07GMT.Thecurrentpagecouldhavechangedinthemeantime.Tip:Toquicklyfindyoursearchtermonthispage,pressCtrl+ForF(Mac)andusethefindbar.

Wednesday,March25,2015

FeasiblyAFewWeeksAwayARemarkableTreatmentForIschemicStroke

March25,20153:40PMETAbout:Athersys,Inc.(ATHX),Includes:CUR,PFE,STEM,MBLTY,OSIR,ROG.VX,CMXI,CYTX

Note:Thisarticlecoversastocktradingatlessthan$4pershareand/orwithlessthana$300millionmarketcap.Pleasebeawareoftherisks.

Introduction

Athersys,Inc.(NASDAQ:ATHX)iscurrentlyengagedinaphaseII,doubleblind,placebocontrolledstudytoexaminethesafetyandpotentialeffectivenessoftheadultstemcellinvestigationalproduct,MultiStem,inadultswho'vesufferedamoderatetomoderatelysevereischemicstroke.AccordingtotheAmericanHeartAssociation,eightysevenpercentofallstrokesareischemic.

WhatIsIschemia\Ischemic

Thehealthybrainrequiresaconstantdeliveryofoxygenandnutrientrichbloodtoeachoneofitsapproximately100billionneurons.Accomplishingthis,andthusensuringnormalbrainfunction,bloodtravelsacrossmultiplebloodvesselstoeverypartofthebrain.Somebloodvessels,however,becomeblockedwithbloodclotsor\andcholesterolplaque,leavingdiscretebrainareastransientlydisconnectedfromtheirbloodsupply.Theresultinglackofoxygenandnutrientsintheseareasisknownasischemia.Neuronsinischemicareasstarverapidlyandrapidlystopfunctioning.

Ischemicstrokesarecausedbyabloodclotinanarteryinthebrain.Treatmentoptionscurrentlyavailableforthistypeofstrokearetimesensitive,whichmakesrecognitionofstrokesymptomsandrapidaccesstomedicalcarecritical.

CurrentlytissuePlasminogenActivator(tPA)isthestandardofcareforstrokeanditbeingatimesensitivetreatmentmakesrapidaccesstomedicalcarecritical.UnfortunatelyintherealworldpatientsoftenarriveatmedicalfacilitiesaftertheoptionfortPAusehasexpired.Thisisoftenthecaseevenwhenapatienthasrapidaccesstomedicalfacilities.It'sestimatedthatlessthan5percentofISvictimscurrentlyreceivetreatmentwithtPA.See:Ischemicstrokestatistics

OneEuropeanclinicaltrialarguesapatientmaystillbenefitfromtPAupto41/2hoursafterastroke.Evenifthisistrue,thewindowtotreatstrokewithtPAisverynarrow.See:StrokeTreatmentwindowWidens

MultiStemcouldhelpstrokevictimsbyofferingawidertreatmentwindow.Theaimistohelppreventlargescaledamagetothebrainafterastrokeandtofacilitatehealingandthepreventionoflongtermdamage.ThefocusisnotonclotremovalasisthecasewithtPA.

Theconsequenceswithouttreatmentaredisabilitiesthatwillvarydependingonstrokelocationandseverity.Patientswilloftensufferphysicaldisabilitiessuchaspartiallossofmotricityorhemiplegia,sensoryloss,languagedisorders,aphasia,visualdisorders,andevenmemoryloss.Levelofrecoverywillvaryfrompatienttopatient.Startingarapidrehabilitationprogramiskeytorecovery.

ResultsfromAnimalModels

Allogeneicstemcells,thetypeusedinMultiStemhavebeenusedtoaidinischemicstrokerecoveryinanimal(rat)models.ThefindingsfromtheresearchbytheUniversityofTexasHealthScienceCenteratHoustonwereespeciallyinterestinginthatallthetreatedratsshowedgreatrecovery,achievingnearnormalresultsfollowingtreatment.Inthismodelthestemcellswereinjectedthirtyminutesafteraninducedischemicstroke.Thesamestudyalsousedacontrolgroupthatwasinjectedwithsalinesolution.Accordingtothestudy,resultswereastounding.Onlyonedayafterthestemcelltreatmentallratsshowedsomefunctionalimprovement.Twoweekslater,thetreatedratshadalmostrecoveredbacktotheirprestrokestate.Whatisintriguingisthattheimprovementhappeneddespitethefactthatthetransplantedstemcellsdidn'tseemtomigratetothedamagedbrain.

Nochangeswerenoticedinthecontrolgroup,stronglyindicatingthattherecoveryintheothergroupwastheresultofthestemcelltreatment.Additionalanimalstudieshaveshownimprovementsinbrainfunction,andhealingofstrokevictimsthroughmechanismsinvolvingthespleen.

Belowareillustrationsshowingtheeffectofthetransplantationofhumanmultipotentadultprogenitorcells(hMAPCs)vs.humanmesenchymalcells(hMSCs).

BiojaxMicrocap

WhyInvestinArrwheadResearch

RNAitechnologyisstillanaffordableinvestment

TheBIZfocusesononesingleinvestmentatatime.ForexampleAthersysisthecurrentinvestmentfocus.Thisstrategygivesthetimerequiredforaninvestortogettoknow\learntheinvestmentandthusreapgreaterreturns.Chasingmomentumalloverthemapisbelievedtoruncountertotheuseofproperduediligence.

Withanyinformationsourceinvestorsareadvisedtousetheirownduediligence.Theindividualinvestorandnotthisblogisresponsibleforhis/herinvestmentchoice.

Articlesonthisblogaren'tdifferentthanopinionpostedonotherinternetvenuesormessageboards.Theyarejustthatopinion.

Dissentingopinioninregardstostocksmentionedonthisblogcanmakeyourinvestmentrisky.Thisblogallowsdissentingcommentstoarticlesandwilltryandgiveanaccurateresponsetodissentingcommentsorquestions.Dissentingopinionscanforcedeeperduediligencepractice.

HereattheBIZthereisnoloveforshorting.Shortingrunscountertoinvestinginabusinessandthisisaninvestingblog.Shortingbynatureisdilutivetothesharecountofanystockandunethicaliffornootherreasonthanthat.

AbouttheBiotechInvestingZone(BIZ)

TheBiotechInvestor

InvestorVilliage

SiliconInvestor

Investorshub

BiotechForums(otherthanYahoo)

BioscienceTechnology

TheLifeSciencesReport

MaximGroup

NIHNationalInstitutesofHealth

ScienceBasedMedicine

MDExpress

AdamFeuerstein'sBiotechBlog

Helpfullinks

0 Mehr NchsterBlog



TheillustrationsshowtheclinicalsuperiorityofthehMAPCsusedinMultiStemovertheMesoblastLimited(MBLTY)hMSCs.ThecurrentMultiStemischemicstrokephaseIItrialusesanIVinfusionasthemethodofdeliveryvs.transplantation,thisisconsideredavastimprovement.

TransplantationofhMAPCsandhMSCsisassociatedwithareducedlossofbraintissue,suggestinganeuroprotectiveeffect.*IntheimagePBS=phosphatebufferedsaline

Below:GlialscarinhibitoryeffectafterhMSCsandhMAPCstransplantation.

Source:TherapeuticeffectsofhMAPCandhMSCtransplantation

Alsosee:MAPCvsMSC

ArealisticneedtodevelopMultiStemforstrokeexists

StatisticsfromtheU.S.CentersforDiseaseControlandPreventionindicatethatstrokeisaleadingcauseofseriousdisabilityandthethirdleadingcauseofmortalityintheU.S.andglobally.Annually,thereareapproximately795,000strokevictimsintheU.S.and15millionglobally(87%ischemicstrokes).Withanincreasinglyobeseandagingpopulation,theclinicalneedandcommercialopportunityisexpectedtoincreasedramaticallyinyearsahead.

Recentprogresstowardthedevelopmentofsaferandmoreeffectivetreatmentsforischemicstrokehasbeendisappointing.Despitethefactthatstrokeisaleadingcauseofseriousdisabilityandthirdleadingcauseofdeath,therehasbeenlittleprogresstowardthedevelopmentoftreatmentsthatimprovetheprognosisforstrokevictims.TheonlyFDAapproveddrugcurrentlyavailableforischemicstrokeistheanticlottingfactor,tPAmentionedabove,whichmustbeadministeredtothepatientwithinthreetofourhoursoftheonsetofthestrokealsomentionedabove.AdministrationoftPAbeyondthistimeframeisnotrecommended,sinceitcancausebleedinginthebrainorevendeath.

AthersysCEOGilVanBokkelenhashadsomepositivecommentsaheadoftheIStrialdatareleasevswhathewassayingaheadoftheulcerativecolitis(UC)trail.ForthosethatrecallpriortotheUCdatareleaseGillikedtomentionMultiStemwouldnotbeeffectiveineachtreatmentareabeingtested.Moreover,GilwouldononevideooccasionjumpoffthetopicoftheUCtrialaltogetherandstarttalkingabouttheIStrailinstead.ThiswasbeforetheUCdatawasevenreleased.GilseemstotakemoreprideinwhathemayviewasacomingsuccessstoryinthecaseoftheIStrail(alogicalassumption).TheseareGil'srecentcommentsstemmingfromtheFebruary10,2015BIOCEOConferenceatthe21minutemark"Weareveryoptimisticaboutthisstudy"(ischemicstroke)."Wethinkit'sgoingtobesuccessfulforalotofreasons...weexpectthatwithinthenextcouplemonthswearegoingtohavethe(ischemicstroke)datasubstantiatethat".Gil'snotbeenknownfor"upselling"AthersysafterheseemstohavetakenittoheartwhathappenedtothecompaniespubliclytradedstockaftertheUCdatawasreleased.SomeinvestorslikelybelievethesenewpositivecommentsweremadeafterGilsawinitialblindedandrawdataanalysisinregardstotheIStrialfromatleastasiteortwothathelpedconductthetrial.Isthisthecase?Nobodyknowsforsure,however,it'sarguablyafairassumptionandonethatmaybesharedbyacompanyinJapanandmaybethereasonthisrecentnewstookplace:AthersysLandsJapanPartnerforStrokeTherapy.

MultiStemhasthepotentialtoaddressthelackofavailabletreatments.Further,MultiStemmaybecomeabestinclasscelltherapy.ThisisbasedonthehMAPCsabilitytodelivertherapeuticbenefitthroughmultiplemechanismsofaction,itsabilitytobedelivered"offtheshelf"likeapharmaceuticalproductanditsconsistentsafetyprofile.MultiStemappearscapableofdeliveringatherapeuticbenefitinmultipleways,suchasthroughtheproductionoffactorsthat:

ProtectdamagedorinjuredneuronsReduceinflammationcommoninischemicinjuryPromotenewbloodvesselformationAugmenttissuerepairandhealing

OneadvantageMultiStemhasoveradultstemcellsharvestedfromthepatientlikethoseusedbyCytoriTherapeutics,Inc.(NASDAQ:CYTX)isthatstrokevictimsareoftenolderandmayhavelessviablestemcells.InthecaseofAthersys,theyuseyounghealthydonors.

BioMedReports

ScienceDaily

ForTheStemCellInvestor

Whoownssharesinthecompany

2015(2)March

FeasiblyAFewWeeksAwayARemarkableTreatment...

January

BlogArchive

AthersysStockTwits

NON_FICTION_1

$ATHX80/20factors2Rochepartnership,4yearsofDD.Don'tlikethatnorealinsiderbuysinover1.5years,thataccountsfor20%

stealin_your_thunder

$ATHXbottomline,Ibelieveinstemcellsandwantthistechnology.PeoplepumpTWTR,FB,AMZN,TSLA!MultiStemcouldsaveyourlovedPoweredby

NameAthersysOsirisTherapeuticsAlnylamPharmaceuticalsCurisIncVerastemInc

Copyright2015,Barchart.comInc.

Barchart.com

Biotechpage

WallStreet.com

EuropeanStemCellNews

Drugdiscoverynews&events



InthecurrentphaseIItrialanindependentsafetycommitteerevieweddatafrompatientsreceivingMultiStemwithinapproximately1to2daysaftertheyhadexperiencedanischemicstroke.Theyfoundthatbothofthedosesevaluatedweresafeandwelltolerated,andtherefore,recommendedproceedingwithhighdoseadministrationtopatientsfortheremainderofthetrial.ThestudyiscurrentlywrappingupatmultiplecentersthroughouttheUnitedStates.TherearesignsthistrialwentverywelldependingonhowinvestorsviewthebelowvideowithThomasDelvin,MDtheDirectorofErlanger'sSoutheastRegionalStrokeCentertalkingaboutMultiStem.

StemCellTreatmentatErlangerfromChattanoogaTimesFreePress PRO

02:39

It'sadoubleblindstudysoonecan'tbesuretilltheresultsarein,however,investorscandrawtheirownconclusion.Athersyshasinvolved140patientsinthisphaseIIMultiStemstudy.Reallylistentowhat'sbeingsaidinthevideoit'sastrongindicationofjusthowadvancedAthersysreallyisintheraceforanewISstroketherapy.

Athersys'sPhaseIIstudyisevaluatingtheeffectivenessofMultiStembeingadministered2436hoursfollowingthestroke.Clearly,thiswouldbeasignificantdevelopmentbecausebythetimemanystrokevictimsevengettothehospitalandareproperlydiagnosed,thetimeframeforusingthecurrentlyavailabletreatmentmayhaveelapsed.

FinancialOutlook

IschemicstrokeisabigopportunityforAthersysasitrepresentsamajorunmetneedandincludesanannualmarketopportunityofmorethan$15Billion.Further,Athersysmayhaveapotentialstroketherapymonopolyhere.Thisissomethinginvestorsshouldconsiderfactoringin.

AthersysenjoysaleadinthedevelopmentraceforanischemicstroketreatmentovercompaniessuchasStemCells,Inc.(NASDAQ:STEM)whichisinpreclinicaltrialsforthesameindication.Inthesetrials,StemCellsInc.hasconductedpreliminarystudiesincollaborationwithprofessorsofneurosurgeryattheStanfordUniversitySchoolofMedicine,successfullydemonstratingthatitshumanneuralstemcellsenhancefunctionalrecoveryafterstrokeinrats.ThisiscertainlyanimportantstepforStemCellsandapotentialvaluedriverforthecompany.

StemCells'marketcapwasalmostexactlythesameasAthersysforawhile,yet,Athersyshasamuchmoreintriguingpipelineaswellasamuchmoreadvancedstrokecandidate.Inaddition,Athersyshasanupcomingcatalystoutsideofstrokeinanorgan(liver)transplanttrialbeingconductedinGermanythatcouldrallythestock.AthersyshasbuiltrelationshipswithsomeverybrightscientistssuchasMarcH.Dahlke,M.D.,Ph.D.

StemCellsinvestorsmightarguethatStemCellsisanundervalued(especiallyattoday'sstockprice),promising,speculativeinvestmentjustlikeAthersys,however,Athersysoffersbettervaluewhenduediligenceisusedinthedecisionmaking.Somedaythatmaynotbethecase,but,todayStemCellsneedstoadvancefurtheralonginclinicaltrialsbeforethatcasecanbemade.

Themarketcapofthetwocompanieswasaboutthesameforawhile,however,theAthersyssharepricehasrecentlystartedtoclimbheadingtowardstheupcomingischemicstroketrialdatarelease,atrialthatinvolvedalotofplanningandspecialequipmenttohandlefrozenstemcells.Evenwiththatsaid,StemCellshasahistoryofburningmoreperquarterwitha$5millionversusa$4.55millionburnrateforAthersysandStemCellsshareshavebeenindecline.

StemCellsfacessomestiffcompetitionfromNeuralstem,Inc.(NYSEMKT:CUR)downtheroadsoifyoulikehumanneuralstemcellstakethetimetoresearchbothcompanies.NeitherStemCellsorNeuralstemareseriouscompetitionforAthersysatthistime.OntheflipsideNeuralstemisseriouscompetitionforStemCellsandniceversa.Neuralstemthebetterinvestmentofthetwocurrently.

Inapastinterview,AthersysCEOGilVanBokkelenwouldnotgiveanexactcostfortheMultiStemtreatmentifitmakesittocommercialization,butsaidthatevenifitcostasmuchas$50,000perpatient,itwouldstillsaveanenormousamountofmoneyindirectandindirecthealthcarecosts.

"ThecostofstroketreatmentintheU.S.isenormous,"hesaid."It'sinthetensofbillionsofdollarseveryyear,andthatnumberisexpectedtorisedramaticallyoverthenextfewyearswithanagingpopulationwheremoreandmorepeoplearesusceptibletostrokeandheartdisease.

"It'sahugemarketopportunityandit'salsoanareawhereit'skindofthequintessentialunmetmedicalneedwheremostpatientsgettheequivalentofmedicalhandholding.That'sjustnotsatisfactory."

IftheabovecommentsbyMr.Bokkelendon'texciteinvestorsmaybethesecommentsbelowandthathemaderecentlywill.KeepinmindMr.Bokkelenisn'tknownforhypingthecompanyratherhe'sknownforbeingpragmatic.Tobehonestthoughhe'sagoodspeakerandassuchagoodsalesman.

"Thestroketrialcouldbeagamechanger,inalotofways.Unlessyou'vehadafamilymemberorlovedonethathassufferedaseriousstroke,it'sdifficulttounderstandjusthowbiganareaofneeditis.Thereareroughly2millionpeopleayearthatsufferastrokeintheU.S.,EuropeandJapan,andveryfewpatientsactuallygettreatedwithrtPA,theclotdissolvingagentthathastobeadministeredwithin34hoursafterthestroke.Thattimeframeisjusttootight,andmostpatientsdon'tgettothedoctorintime.WeandourcollaboratorshavepublishedworkfrompreclinicalstudiesthatsuggeststhatwecangiveMultiSteminamorepracticaltimeframefollowingastroke,perhapsseveraldays.Ifithelpspatientsrecover,itcouldchangestrokeclinicalcare,andit'salsoanenormouscommercialopportunitywhichissomethingthatgetsourshareholdersveryexcited."

NewlegislationforregenerativemedicineinJapan\recentpartnering

RecentlyreformsinJapanesepharmaceuticallegislationdesignedtoacceleratethedevelopmentandcommercializationofregenerativemedicineshascausedsomeexcitementforthoseinvestedinthisfield.Athersys'sfreshpartnershipwithChugaiPharmaceuticalswillenableAthersystopursuethissignificant



opportunityforMultiSteminJapan,andinvestorsshouldanticipatefurtherdevelopmentsonthecommercialfrontin2015.

AthersyshasbeenlookingtotakeadvantageofrecentlegislationinJapanthat'sfavorabletostemcelltherapyreachingpatientsinanexpeditedfashion.ThepartnershipwithChugaicertainlyshouldbeabletohelpAthersysinthatendeavor.ThemajorityownershipofChugaiisheldbyRocheGroup(ROG.VX)makingthisaveryheavyhittingdealforAthersys.Rochehasamarketcapofover$221billionandAthersyshasapromisingpipelinetheycouldeasilybecomeinterestedin.ForChugaitopartnerwithAthersysinJapanlikelymeansRochegavethegreenlight.IncomparisonPfizerhasamarketcapof$208billion.

ThereisareasonEdisonEquityResearchjustraisedtheAthersyspricetargetto$3.75aheadofthedatabeingreleased.Fordetailssee:Edison.

InvestorsshouldlookintohowEdisoncalculatedit'spricetarget.They'vegivenoddsthatcanbecalculatedouttobeabout$15.40pershareafterdataisreleased.Atleastthat'sthewayitlookswhenyoupluginthelogic\oddsusedindeterminingthelowerpricetargetpriortodatabeingreleased.The$15.40projectedtarget(aftergooddatarelease)isanestimatethatwascalculatedbeforetheraisedpredatapricetargetwasreleasedon3/11/2015meaningthepricetargetcouldnowbehigherafterdataisreleased.

AthersysInc,recentlyraised$10millionfromthepartnershipdealwithChungai.Theproceedsfromtheofferingwilllikelybeusedtosupporttheongoingandproposedprograms(inJapan)forMultiStem.Athersysstockrecentlytradedupto$3.43edgingclosertowhereittradedonJanuary9th,2014.ThehighpershareonJanuary9th2014was$4.33sothestockisstilldiscountedinsomeinvestorseyes.

Resultsfromtheischemicstroketrialwillbeasignificanteventthatwillnodoubtreratethestock.ThelackofashareofferinginthefaceofthisrecentsharepriceclimbseemstosuggestthatAthersysmanagementissecureinthecompaniesfuture.ArecentSeekingAlphaarticlesuggestedtheAthersyssharepriceshouldsoar400%fromaboutthe~$3.00markorthatAthersyssharescouldsinktoaboutthe$1area.ThedirectionofthesharepricewillbesubjecttothecomingdatareleasefromtheIStrial.Thatsamearticlemadewhatlookstobean"offthewallcomment"aboutthepotentialforAthersystobecomeagoingconcernifthedataweretofargonetothenoefficacyside.ThatseemsabitextremeconsideringthedepthoftheAthersyspipelinethatincludestechnologiesalreadyinusesuchasMap3technologyandotherprogramsoutsideofMultiStemsuchasthesmallmoleculeprogramortheantiobesitydrugcandidate.TherealfactorthatwasleftoutoftheSeekingAlphaarticlewastheearliermentionedlivertransplanttrialthat'songoinginGermany.Athersysstillhasmorethanoneshotongoalandinvestorswouldbewisetakenote.

Onamorepositivenote:MultiStemmaygostraightintocommercializationforhumanuseinJapan,ifthecurrentischemicstroketrialconfirmssafetyandefficacytosomedegree.That'sexcitingbecauseJapanistheworld'ssecondlargestmaturehealthcaremarketbehindonlytheUnitedStates.

TherecentbillinJapanallowstheJapaneseGovernmenttogiveconditionalapprovaltoproductssuchasMultiStemiftheirsafetyisconfirmedinclinicaltrials,asmayoccuroncompletionofPhase2.Thisshouldsubstantiallyreducethetimeandcostofdevelopingstemcelltherapies,withaslittleasoneclinicalstudyrequiredtodemonstratesafetyandmeaningfultherapeuticbenefit,inordertogainprovisionalapprovalandreimbursementinJapan.(Ifthat'sneededatallaheadofusewhilethetrialgoesoninJapan)

Risks

MultiStemhadapoorshowingintheulcerativecolitistrial.Thataloneshouldhaveinvestorssiftingthrough,reading,listening,andwatchingforscientificfactstocomparetheIBDtrialtotheIStrial.IfbeingfairtothemselvesandtoAthersysinvestorswillquicklyacknowledgeaonedosecuresallmentalityforahardtotreatgrouplikethosepatientsintheIBDtrialwassetupforfailure,notcompletefailure,learningstilloccurred.Investorsshouldalsonoteitwasn'tAthersyswhoranthetrialitwasPfizer.MakenomistakeAthersysandit'sMultiStemmaystillhaveaplaceintreatingIBD.ThisisahighlyplausibleargumenttomakegivenMesoblastdecidedtocarryonwiththeOsirisTherapeutics,Inc.(OSIR)phaseIIItrialforCrohn'sDisease,also,aformofIBD.Mesoblastusesacellthat'sverysimilartothatusedinAthersys'sMultiStemsoit'sfeasibleAthersysforgesaheadespeciallyonagoodshowingfromMesoblastanditsphaseIIItrialforcrohn'sdisease.

JasonKolbertManagementDirectoratMaximGroupjustsaidthefollowingwhenactingasamoderatorandinterviewingtheCEOofTXCell,acompanythathasmadeprogressintheareaofcrohn'sdisease."HebelievesMultiStemworksforUC,but,thedosingwasnotdoneright".See:Thelivewebcast

Whilescientistspointtothevalueofanimalmodels,theyalsoacknowledgethatnoanimalmodelfullyrecapitulateshumanneurologicaldisease.

Animalstudiesthatproducepromisingresultsfordrugsfrequentlyfailinclinicaltrials.Whilethedifferencesbetweenhumanandnonhumanspeciesmayaccountforsomeofthefailures,anewreportbytheInstituteofMedicine(IOM)callsattentiontofaultyexperimentaldesigns,questionablestatisticalanalysis,andthetendencyofjournalstopreferpublishingpositiveresults.InthecaseofAthersys,whilethisisaconcerntheyhavetodatebeenpronetogivingmorethoughttotrialdesignthanmanyothersmallbiotechcompanies.Alsomoreandmorehumanclueshavebecomeavailableforthosewholookthatthistrialwillsucceed.

CostantinoIadecola,MD,professorofneurologyandneuroscienceatWeillCornellMedicalCollege,notedthatthepathobiologyofstrokecanbereproducedeffectivelyinanimalmodels,althoughthemechanismbywhichtheocclusiondevelopsinhumansmaynotbemimickedexactly.Effortsarebeingmadetomorecloselyalignanimalmodelswithhumanstroke,hesaid.Forexample,treatmentsareincreasinglyadministeredtohypertensive,diabetic,andagedanimalsinanefforttoaccountforstrokeriskfactors.Butunfortunatelymanypharmaceuticalcompanieshaveabandonedthesearchforstroketreatmentsduetothefailureofclinicaltrialstoproduceeffectiveresults.

TheaboveshouldbodewellforAthersys.Asitspeaksoflimitedcompetitionaswellasanimalmodelsbeingeffectiveforthisapplication.

WhenitcomestoearlyscientificevidencesuggestinganoutcomeinregardstotheAthersyshumanIStrialinvestorscanfindit.Takealookhere:Stemcellsshowpromiseforstrokeinpilotstudy.It'sthefirstUnitedKingdomstudyofstemcelltreatmentforacutestroketobepublishedandthefirsttrialofitskindinhumans.Here'sanotherpotentiallookintothefuture:InternationalStrokeConferenceOralAbstracts.Additionally,ifinvestorslookbackinthisarticleatthevideocontainingaqualifiedexpertinregardstohowAthersysisdoingfromThomasDelvin,MDtheDirectorofErlanger'sSoutheastRegionalStrokeCentertheyshouldbeexcited!

Usuallycompetitionisariskfordevelopingbiotechcompanies,however,Cytomedix,Inc.(CMXI)wastheonlyrealcompetitortoAthersysforanischemicstroketreatment.Cytomedix'scoretechnologyusedasingleintracartoidinfusiontotreatischemicstrokebut,theyhavestopfundingfortheirischemicstroketherapyafterlastyear.OnehastobelievethedeliveryrouteCytomedixusedwasalargepartofthefundingstoppage.IntracartoidinfusionisfarlessattractivethanAthersys'sintravenousinfusionandfindingvolunteersmusthavebeentoughincomparison.Cytomedix'streatmenttherapyisalsoadministeredroughlytwoweeksafterexperiencingastroke.Cytomedix'stherapyisclearlynotasconvenientandwholikestowaitfortreatmentletalonegobackfortreatmentthat'suncomfortableandunproven?

AthersysandCytomedixhadbothbeenassessedbyanalystsasbeingthetwomaincompanieswithapotentialblockbusterstroketreatmentonhand.TodayonlyAthersysisstanding.

Conclusion



NewerPosts OlderPostsHome

Subscribeto:Posts(Atom)

[email protected]:37PM 2comments:

TheAthersyspipelinecontinuestogrowandmature,andinvestorsarebeginningtorecognizeandappreciatethepotentialvalueoftheportfolio.IfAthersysstaysfocusedandachieveswhattheyarecapableof,investorsshouldbeconfidentthatonedaysoonAthersyswillberecognizedasagloballeaderintheindustry.

Disclosure:IamlongATHX.Iwrotethisarticlemyself,anditexpressesmyownopinions.Iamnotreceivingcompensationforit.Ihavenobusinessrelationshipwithanycompanywhosestockismentionedinthisarticle.

Additionaldisclosure:Scienceisstillevolvingregardingstemcellsandmanyscientificpointsaredebatedincludingsomecontainedinthisarticle.TothebestofmyknowledgeIputforthaccurateinformation

+1 Recommend this on Google

AwesomeInc.template.PoweredbyBlogger.